Tumor immunotherapy gets significant breakthroughs, particularly with the approval of immune checkpoint inhibitors (ICIs) and T-cell therapy. Scientists showed that some solid tumors targeting programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) molecules have a long-lasting clinical response and prolonged survival. Creative Biolabs provides specialized services in T cell cytotoxicity assay to successfully meet the requirements of your trial in the most effective and cost-efficient manner possible.
Herpes virus entry mediator (HVEM) and B and T lymphocyte attenuator (BTLA) are new co-inhibitory molecules in the anti-tumor immune response. Many immune cells such as T-cells can express these two molecules, in which signaling through BTLA is associated with inhibition of their activation. The binding of HVEM to CD160 on T-cells is also associated with an inhibition response. The HVEM network includes many other partners, such as LIGHT, lymphotoxin α (LTα), or CD160. Stimulation of HVEM on T-cells by any of its ligands is associated with proliferation, survival, and inflammatory cytokines production, such as interleukin-2 (IL-2) and interferon-gamma (IFN-γ).
Creative Biolabs has some methods to detect cytotoxic and cytostatic effects of different compounds and measure cellular viability. These methods include cell membrane permeability, cell adherence, cell adherence, co-enzyme production, dye uptake, metabolic activities, enzyme releasing, cell adherence, DNA synthesis, and nucleotide uptake activity assay.
We provide two main detection methods.
Creative Biolabs has a professional immune checkpoint development team with extensive experience in immune checkpoint functional assays for years. We have experienced experts and advanced platforms that can provide excellent services. If you want to know more information, please directly contact us.
All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.